HTBX
$1.14
Heat Biologics
$.04
3.64%
HTBX
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.04)
Revenue:  N/A
Monday
Feb 8
0:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when HTBX reports earnings?
Beat
Meet
Miss

Where is HTBX's stock price going from here?
Up
Flat
Down
Stock chart of HTBX
Analysts
Summary of analysts' recommendations for HTBX
Score
Grade
Pivots
Resistance
$1.26
$1.22
$1.18

$1.14

Support
$1.10
$1.06
$1.02
Tweet
Growth
Description
Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases. The Company's products under development include HS-110 for the treatment of non-small cell lung cancer, HS-410 for the bladder cancer treatment, HS-310 to treat ovarian cancer and HS-510 for treating triple negative breast cancer. Heat Biologics, Inc. is based in Chapel Hill, North Carolina.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli Lilly